<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CAEEL Surveillance Immunity Project - Comprehensive Curation Recommendations - AI Gene Review Projects</title>
    <style>
        :root {
            --color-accept: #22c55e;
            --color-remove: #ef4444;
            --color-modify: #f97316;
            --color-primary: #3498db;
            --bg-light: #f9fafb;
            --border-color: #e5e7eb;
            --text-muted: #6b7280;
            --text-primary: #111827;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background-color: #ffffff;
            padding: 2rem;
            max-width: 1200px;
            margin: 0 auto;
        }

        .breadcrumb {
            margin-bottom: 1.5rem;
            font-size: 0.875rem;
            color: var(--text-muted);
        }

        .breadcrumb a {
            color: var(--color-primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .header {
            border-bottom: 2px solid var(--border-color);
            padding-bottom: 1.5rem;
            margin-bottom: 2rem;
        }

        h1 {
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: 0.5rem;
            color: #1f2937;
        }

        h2 {
            font-size: 1.75rem;
            font-weight: 600;
            margin-top: 2rem;
            margin-bottom: 1rem;
            color: #1f2937;
            border-bottom: 1px solid var(--border-color);
            padding-bottom: 0.5rem;
        }

        h3 {
            font-size: 1.25rem;
            font-weight: 600;
            margin-top: 1.5rem;
            margin-bottom: 0.75rem;
            color: #374151;
        }

        h4 {
            font-size: 1rem;
            font-weight: 600;
            margin-top: 1.25rem;
            margin-bottom: 0.5rem;
            color: #4b5563;
        }

        p {
            margin-bottom: 1rem;
        }

        a {
            color: var(--color-primary);
            text-decoration: none;
        }

        a:hover {
            text-decoration: underline;
        }

        /* Gene symbol links */
        .content a[href*="/genes/"] {
            background-color: #dbeafe;
            padding: 0.125rem 0.375rem;
            border-radius: 0.25rem;
            font-weight: 500;
        }

        .content a[href*="/genes/"]:hover {
            background-color: #bfdbfe;
        }

        ul, ol {
            margin-bottom: 1rem;
            padding-left: 2rem;
        }

        li {
            margin-bottom: 0.25rem;
        }

        code {
            background: #f4f4f4;
            padding: 0.125rem 0.375rem;
            border-radius: 0.25rem;
            font-family: 'SFMono-Regular', Consolas, 'Liberation Mono', Menlo, monospace;
            font-size: 0.875em;
        }

        pre {
            background: #1f2937;
            color: #f9fafb;
            padding: 1rem;
            border-radius: 0.5rem;
            overflow-x: auto;
            margin-bottom: 1rem;
        }

        pre code {
            background: none;
            padding: 0;
            color: inherit;
        }

        blockquote {
            border-left: 4px solid var(--color-primary);
            margin-left: 0;
            padding-left: 1.5rem;
            color: #4b5563;
            font-style: italic;
            margin-bottom: 1rem;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            margin: 1.5rem 0;
        }

        th, td {
            border: 1px solid var(--border-color);
            padding: 0.75rem;
            text-align: left;
        }

        th {
            background-color: var(--bg-light);
            font-weight: 600;
            color: var(--text-muted);
            text-transform: uppercase;
            font-size: 0.75rem;
            letter-spacing: 0.05em;
        }

        tr:nth-child(even) {
            background-color: #f9fafb;
        }

        tr:hover {
            background-color: #f3f4f6;
        }

        /* Mermaid diagrams */
        .mermaid {
            text-align: center;
            margin: 2rem 0;
            background: white;
            padding: 1.5rem;
            border-radius: 0.5rem;
            border: 1px solid var(--border-color);
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        /* Warnings section */
        .warnings {
            background-color: #fef3c7;
            border: 1px solid #fde68a;
            border-radius: 0.5rem;
            padding: 1rem;
            margin-bottom: 2rem;
        }

        .warnings h3 {
            color: #92400e;
            margin-top: 0;
            margin-bottom: 0.5rem;
            font-size: 1rem;
        }

        .warnings ul {
            margin-bottom: 0;
            color: #78350f;
        }

        /* Task lists (checkboxes) */
        li input[type="checkbox"] {
            margin-right: 0.5rem;
        }

        /* Status badges */
        .badge {
            display: inline-block;
            padding: 0.25rem 0.625rem;
            border-radius: 9999px;
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
        }

        .badge-success {
            background-color: #d1fae5;
            color: #065f46;
        }

        .badge-warning {
            background-color: #fef3c7;
            color: #92400e;
        }

        .badge-info {
            background-color: #dbeafe;
            color: #1e40af;
        }

        /* Content wrapper */
        .content {
            margin-bottom: 2rem;
        }

        /* Footer */
        footer {
            margin-top: 3rem;
            padding-top: 1.5rem;
            border-top: 1px solid var(--border-color);
            color: var(--text-muted);
            font-size: 0.875rem;
            text-align: center;
        }

        footer small {
            display: block;
        }
    </style>
    <!-- Mermaid.js for diagram rendering -->
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            themeVariables: {
                primaryColor: '#3498db',
                primaryTextColor: '#fff',
                primaryBorderColor: '#2c3e50',
                lineColor: '#333',
                secondaryColor: '#ecf0f1',
                tertiaryColor: '#f39c12'
            },
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <nav class="breadcrumb">
        <a href="../index.html">Home</a> &raquo;
        <a href="index.html">Projects</a> &raquo;
        CAEEL Surveillance Immunity Project - Comprehensive Curation Recommendations
    </nav>

    <header class="header">
        <h1>CAEEL Surveillance Immunity Project - Comprehensive Curation Recommendations</h1>
        
    </header>

    
    <div class="warnings">
        <h3>Warnings (1)</h3>
        <ul>
            
            <li>Ambiguous symbol &#39;daf-16&#39; found in species: CAEEL, worm. Add &#39;species: [CAEEL]&#39; to frontmatter to resolve.</li>
            
        </ul>
    </div>
    

    <div class="content">
        <h1 id="caeel-surveillance-immunity-project-comprehensive-curation-recommendations">CAEEL Surveillance Immunity Project - Comprehensive Curation Recommendations</h1>
<h2 id="overview">Overview</h2>
<p>This document consolidates all curation recommendations across the 18 surveillance immunity genes, organized by action type: <strong>ACCEPT, REMOVE, MODIFY, NEW, KEEP_AS_NON_CORE, MARK_AS_OVER_ANNOTATED</strong>.</p>
<p>Each recommendation includes:<br />
- <strong>Current state</strong>: What the YAML file currently has<br />
- <strong>Action</strong>: What should be done (ACCEPT, REMOVE, MODIFY, NEW, etc.)<br />
- <strong>Justification</strong>: Why this action is recommended<br />
- <strong>Specific suggestion</strong>: For MODIFY, the proposed replacement term(s)<br />
- <strong>Evidence</strong>: Supporting <a href="../../genes/human/publications/publications-ai-review.html">publications</a> or GO logic</p>
<hr />
<h1 id="priority-1-core-p38-mapk-cascade">PRIORITY 1: Core p38 MAPK Cascade</h1>
<h2 id="gene-1-pmk-1-q17446-p38-mapk">Gene 1: <a href="../../genes/worm/pmk-1/pmk-1-ai-review.html">pmk-1</a> (Q17446) - p38 MAPK</h2>
<p><strong>Status</strong>: ‚úÖ <strong>PUBLICATION-READY</strong> - No changes recommended</p>
<h3 id="summary">Summary</h3>
<p>All 74 annotations are well-curated with appropriate evidence codes and clear distinction between core immune functions and peripheral roles. The review demonstrates exemplary GO curation standards.</p>
<h3 id="key-accepted-functions">Key Accepted Functions</h3>
<ul>
<li>Kinase activity (GO:0004674, GO:0004675, GO:0005524)</li>
<li>p38MAPK cascade (GO:0038066) - primary core function</li>
<li>Innate immune response (GO:0045087)</li>
<li>Antibacterial defense (GO:0140367, GO:0050829, GO:0050830)</li>
<li>Antifungal defense (GO:0050832)</li>
<li>ATF-7 binding (GO:0051019, GO:0061629)</li>
<li>Oxidative stress response (GO:0006979, GO:0000302, GO:0000303)</li>
</ul>
<h3 id="recommendation">Recommendation</h3>
<p><strong>ACCEPT AS-IS</strong> - No MODIFY, NEW, or REMOVE actions needed.</p>
<hr />
<h2 id="gene-2-sek-1-g5edf7-mapkk">Gene 2: <a href="../../genes/worm/sek-1/sek-1-ai-review.html">sek-1</a> (G5EDF7) - MAPKK</h2>
<p><strong>Status</strong>: ‚úÖ <strong>PUBLICATION-READY</strong> - No changes recommended</p>
<h3 id="summary_1">Summary</h3>
<p>46 annotations comprehensively capture SEK-1's role as the dual-specificity MAPKK in the p38 cascade. All major functions properly supported by evidence.</p>
<h3 id="key-accepted-functions_1">Key Accepted Functions</h3>
<ul>
<li>Dual-specificity kinase activity (GO:0004712 with IDA evidence)</li>
<li>NSY-1 binding (GO:0031435, IPI evidence)</li>
<li>p38MAPK cascade (GO:0038066)</li>
<li>Innate immune response</li>
<li>Bacterial and fungal defense responses</li>
<li>Stress responses (oxidative, osmotic, toxic substance)</li>
</ul>
<h3 id="recommendation_1">Recommendation</h3>
<p><strong>ACCEPT AS-IS</strong> - Curation is complete and accurate. No revisions needed.</p>
<hr />
<h2 id="gene-3-nsy-1-q21029-map3kask1">Gene 3: <a href="../../genes/worm/nsy-1/nsy-1-ai-review.html">nsy-1</a> (Q21029) - MAP3K/ASK1</h2>
<p><strong>Status</strong>: ‚ö†Ô∏è <strong>REVIEW-READY</strong> - 1 MODIFY recommendation</p>
<h3 id="summary_2">Summary</h3>
<p>49 annotations comprehensively reviewed. One issue identified regarding GO term specificity.</p>
<h3 id="action-item">Action Item</h3>
<h4 id="modify-go0004712-protein-serinethreoninetyrosine-kinase-activity">MODIFY: GO:0004712 Protein serine/threonine/tyrosine kinase activity</h4>
<ul>
<li><strong>Current State</strong>: Annotated with IDA evidence (PMID:11751572)</li>
<li><strong>Issue</strong>: The term includes "/tyrosine" component, but NSY-1 is NOT a tyrosine kinase</li>
<li><strong>Recommendation</strong>: MODIFY to more specific term</li>
<li><strong>Proposed Replacement</strong>:</li>
<li><strong>Remove</strong>: GO:0004712 (protein serine/threonine/tyrosine kinase activity)</li>
<li><strong>Keep</strong>: GO:0004709 (MAP kinase kinase kinase activity) - already present</li>
<li><strong>Or Keep</strong>: GO:0004674 (protein serine/threonine kinase activity) - already present</li>
<li><strong>Justification</strong>: EC classification 2.7.11.25 is Ser/Thr kinase only; the "/tyrosine" component is misleading</li>
<li><strong>Evidence</strong>: UniProt annotation and kinase classification</li>
</ul>
<h3 id="all-other-annotations">All Other Annotations</h3>
<p><strong>ACCEPT</strong> - 48 remaining annotations are well-supported and appropriately distinguished between core immune functions and secondary roles.</p>
<h3 id="recommendation_2">Recommendation</h3>
<p><strong>1 MODIFY, 48 ACCEPT</strong> - Remove the misleading tyrosine kinase term while retaining appropriate Ser/Thr kinase annotations.</p>
<hr />
<h2 id="gene-4-tir-1-q86da5-sarm1-homologtir-adaptor">Gene 4: <a href="../../genes/worm/tir-1/tir-1-ai-review.html">tir-1</a> (Q86DA5) - SARM1 Homolog/TIR Adaptor</h2>
<p><strong>Status</strong>: ‚úÖ <strong>PUBLICATION-READY</strong> - Comprehensive review complete</p>
<h3 id="summary_3">Summary</h3>
<p>48 annotations excellently capture TIR-1's role as the upstream adaptor in immune signaling. Clear distinction between core innate immunity functions and secondary developmental roles.</p>
<h3 id="key-accepted-functions_2">Key Accepted Functions</h3>
<ul>
<li>NAD+ hydrolase activity (GO:0035521, GO:0003939)</li>
<li>NSY-1 recruitment and activation</li>
<li>TIR domain signaling (GO:0008406, GO:0004674)</li>
<li>Innate immune response (GO:0045087)</li>
<li>Bacterial and fungal defense</li>
<li>Signaling pathway regulation</li>
</ul>
<h3 id="special-note-on-assembly-functions">Special Note on Assembly Functions</h3>
<p>The review correctly identifies and accepts annotations for:<br />
- Protein complex assembly (GO:0006461)<br />
- Kinase complex assembly<br />
- MAPK signaling assembly</p>
<p>These represent TIR-1's scaffolding function, which is distinct from but complementary to its enzymatic activity.</p>
<h3 id="recommendation_3">Recommendation</h3>
<p><strong>ACCEPT AS-IS</strong> - All annotations are well-justified. No MODIFY, NEW, or REMOVE actions needed.</p>
<hr />
<h2 id="gene-5-atf-7-q86md3-bzip-transcription-factor">Gene 5: <a href="../../genes/worm/atf-7/atf-7-ai-review.html">atf-7</a> (Q86MD3) - bZIP Transcription Factor</h2>
<p><strong>Status</strong>: ‚úÖ <strong>PUBLICATION-READY</strong> - Exemplary curation</p>
<h3 id="summary_4">Summary</h3>
<p>30 annotations represent exemplary GO curation with clear integration of ChIP-seq evidence and mechanistic understanding of ATF-7's phosphorylation-dependent switch from repressor to activator.</p>
<h3 id="key-accepted-functions_3">Key Accepted Functions</h3>
<ul>
<li>DNA-binding transcription factor activity (GO:0000981, GO:0035497)</li>
<li>PMK-1 interaction (GO:0051019, IPI evidence)</li>
<li>Positive regulation of innate immunity (GO:0045089)</li>
<li>Negative regulation of innate immunity (GO:0045824)</li>
<li>Bacterial defense responses (GO:0050829 - 3 independent <a href="../../genes/human/publications/publications-ai-review.html">publications</a>)</li>
<li>Gene expression regulation (GO:0010468)</li>
<li>CRE-binding (GO:0035497)</li>
</ul>
<h3 id="special-strength-evidence-integration">Special Strength: Evidence Integration</h3>
<p>The annotations properly integrate:<br />
- Genetic evidence (IMP from infection screens)<br />
- Biochemical evidence (IPI for PMK-1 binding)<br />
- Genomic evidence (ChIP-seq from PMID:30789901)<br />
- Comparative evidence (ISS from <a href="../../genes/human/ATF2/ATF2-ai-review.html">ATF2</a> orthology)</p>
<h3 id="recommendation_4">Recommendation</h3>
<p><strong>ACCEPT AS-IS</strong> - This is a model for how complex transcriptional regulators should be annotated. All core and peripheral functions appropriately distinguished.</p>
<hr />
<h2 id="gene-6-skn-1-p34707-nfe2l2nrf2-ortholog">Gene 6: <a href="../../genes/worm/skn-1/skn-1-ai-review.html">skn-1</a> (P34707) - <a href="../../genes/human/NFE2L2/NFE2L2-ai-review.html">NFE2L2</a>/NRF2 Ortholog</h2>
<p><strong>Status</strong>: ‚úÖ <strong>PUBLICATION-READY</strong> - Exceptional curation quality</p>
<h3 id="summary_5">Summary</h3>
<p>76 annotations represent exceptional GO curation of a complex, multifunctional gene with clear distinction between:<br />
- Core oxidative/xenobiotic stress response<br />
- Developmental functions (mesendoderm specification)<br />
- Longevity-related functions<br />
- Isoform-specific roles</p>
<h3 id="key-accepted-functions_4">Key Accepted Functions</h3>
<p><strong>Core Stress Response</strong>:<br />
- DNA-binding transcription factor activity (GO:0000981, GO:0000978)<br />
- Oxidative stress response (GO:0006979, IMP evidence)<br />
- Superoxide response (GO:0000303)<br />
- Cellular detoxification (GO:1990748, GO:0035521)<br />
- Phase II detoxification gene regulation<br />
- WDR-23/CUL4 ubiquitin ligase binding (GO:0031625, IPI)<br />
- PMK-1 phosphorylation (GO:0051019)</p>
<p><strong>Developmental Functions (KEEP_AS_NON_CORE)</strong>:<br />
- Mesendoderm development (GO:0048382, IGI evidence from maternal context)<br />
- Endodermal specification (GO:0001714)</p>
<p><strong>Stress Integration</strong>:<br />
- Proteasomal dysfunction response<br />
- ER stress response (GO:0036500, GO:0036498)<br />
- Metal response</p>
<h3 id="recommendation_5">Recommendation</h3>
<p><strong>ACCEPT AS-IS</strong> - All 76 annotations are well-supported. The two MODIFY actions for vague "protein binding" terms are appropriate refinements but not critical.</p>
<p><strong>Optional Enhancement</strong>:<br />
- Consider adding GO:1902857 (positive regulation of chromatin assembly) if CBP-1 coactivator recruitment is to be emphasized<br />
- But current annotations adequately capture all major functions</p>
<hr />
<h1 id="priority-2-surveillance-immunity-pathway">PRIORITY 2: Surveillance Immunity Pathway</h1>
<h2 id="gene-7-zip-2-q21148-bzip-surveillance-tf">Gene 7: <a href="../../genes/worm/zip-2/zip-2-ai-review.html">zip-2</a> (Q21148) - bZIP Surveillance TF</h2>
<p><strong>Status</strong>: üü° <strong>GOOD QUALITY</strong> - 3-5 MODIFY recommendations</p>
<h3 id="summary_6">Summary</h3>
<p>22 annotations with excellent coverage of ZIP-2's unique surveillance immunity role (translation disruption sensing). However, several vague "protein binding" terms should be made specific.</p>
<h3 id="action-items">Action Items</h3>
<h4 id="modify-1-go0005515-protein-binding-with-atf-2-interaction">MODIFY #1: GO:0005515 "protein binding" with ATF-2 interaction</h4>
<ul>
<li><strong>Current</strong>: GO:0005515 (protein binding), IPI evidence</li>
<li><strong>Issue</strong>: Too vague for a specific bZIP dimerization</li>
<li><strong>Recommendation</strong>: MODIFY to GO:0046983 (protein dimerization activity)</li>
<li><strong>Justification</strong>: ZIP-2 forms obligate dimers through leucine-zipper domain; ATF-2 is likely referring to ATF-7 (the worm ortholog of <a href="../../genes/human/ATF2/ATF2-ai-review.html">ATF2</a>)</li>
<li><strong>Evidence</strong>: bZIP protein structure; IPI evidence is appropriate for dimerization</li>
</ul>
<h4 id="modify-2-go0005515-protein-binding-with-cebp-2">MODIFY #2: GO:0005515 "protein binding" with CEBP-2</h4>
<ul>
<li><strong>Current</strong>: GO:0005515 (protein binding), IPI evidence</li>
<li><strong>Issue</strong>: Vague; this is the critical heterodimerization partner</li>
<li><strong>Recommendation</strong>: MODIFY to GO:0046983 (protein dimerization activity)</li>
<li><strong>Justification</strong>: ZIP-2/CEBP-2 heterodimer is the transcriptionally active complex; essential for immune response</li>
<li><strong>Evidence</strong>: PMID:21408619, biochemical characterization of heterodimer</li>
</ul>
<h4 id="modify-3-go0005515-protein-binding-with-additional-partners">MODIFY #3: GO:0005515 "protein binding" with additional partner(s)</h4>
<ul>
<li><strong>Current</strong>: Unspecified additional protein binding annotations</li>
<li><strong>Issue</strong>: Lack specificity about binding partners</li>
<li><strong>Recommendation</strong>: Either make specific (GO:0046983 for dimerization) or REMOVE if partner not functionally important</li>
<li><strong>Evidence</strong>: Determine from literature which interactions are critical for immunity</li>
</ul>
<h3 id="mark-as-over-annotated">Mark as Over-Annotated</h3>
<h4 id="mark_as_over_annotated-go0003677-dna-binding">MARK_AS_OVER_ANNOTATED: GO:0003677 "DNA binding"</h4>
<ul>
<li><strong>Current</strong>: Parent term for more specific binding</li>
<li><strong>Issue</strong>: General term when more specific RNA Pol II terms exist</li>
<li><strong>Recommendation</strong>: MARK_AS_OVER_ANNOTATED if GO:0000981 (specific Pol II TF activity) is present</li>
<li><strong>Evidence</strong>: GO hierarchy suggests specific terms preferred</li>
</ul>
<h4 id="mark_as_over_annotated-go0006351-dna-templated-transcription">MARK_AS_OVER_ANNOTATED: GO:0006351 "DNA-templated transcription"</h4>
<ul>
<li><strong>Current</strong>: Very general transcription term</li>
<li><strong>Issue</strong>: Parent term when more specific GO:0006357 exists</li>
<li><strong>Recommendation</strong>: MARK_AS_OVER_ANNOTATED</li>
<li><strong>Evidence</strong>: GO specificity principle</li>
</ul>
<h3 id="new-annotations-to-consider">New Annotations to Consider</h3>
<h4 id="new-go0000122-negative-regulation-of-transcription-by-rna-pol-ii">NEW: GO:0000122 "negative regulation of transcription by RNA Pol II"</h4>
<ul>
<li><strong>Rationale</strong>: ZIP-2 normally acts as repressor in uninfected state; activation by translation disruption</li>
<li><strong>Evidence</strong>: If literature supports ZIP-2 repressor activity in normal conditions</li>
<li><strong>GO Term</strong>: GO:0000122 (negative regulation of transcription, RNA polymerase II)</li>
<li><strong>Evidence Code</strong>: IMP from expression analysis</li>
</ul>
<h4 id="new-go0090090-negative-regulation-of-canonical-wnt-signaling-pathway">NEW: GO:0090090 "negative regulation of canonical Wnt signaling pathway"</h4>
<ul>
<li><strong>Rationale</strong>: If ZIP-2 has developmental or stress-related Wnt pathway interactions</li>
<li><strong>Evidence</strong>: Require specific literature support</li>
<li><strong>Status</strong>: OPTIONAL - only if experimental evidence exists</li>
</ul>
<h3 id="recommendation_6">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 17 core annotations (translation sensing, immune gene activation, heterodimerization with CEBP-2)<br />
- <strong>MODIFY</strong>: 3 protein binding ‚Üí GO:0046983 (protein dimerization activity)<br />
- <strong>MARK_AS_OVER_ANNOTATED</strong>: 2 generic DNA binding and transcription terms<br />
- <strong>NEW</strong>: Consider GO:0000122 if ZIP-2 repressor activity is documented<br />
- <strong>Overall Quality</strong>: Good; consolidation of redundant terms recommended</p>
<hr />
<h2 id="gene-8-cebp-2-q8ig69-cebp">Gene 8: <a href="../../genes/worm/cebp-2/cebp-2-ai-review.html">cebp-2</a> (Q8IG69) - C/EBP</h2>
<p><strong>Status</strong>: üü° <strong>GOOD QUALITY</strong> - 5-8 MODIFY recommendations</p>
<h3 id="summary_7">Summary</h3>
<p>31 annotations with strong coverage of C/EBP function. However, 8 instances of generic "protein binding" annotations should be consolidated into more specific molecular function terms.</p>
<h3 id="action-items_1">Action Items</h3>
<h4 id="modify-1-8-consolidate-8-protein-binding-annotations">MODIFY #1-8: Consolidate 8 "protein binding" annotations</h4>
<ul>
<li><strong>Current</strong>: Multiple GO:0005515 (protein binding) annotations with various evidence codes</li>
<li><strong>Issue</strong>:</li>
<li>Excessive redundancy (same GO term multiple times)</li>
<li>Vague molecular function description</li>
<li>Lose specificity about binding partners</li>
<li><strong>Recommendation</strong>: Consolidate into specific dimerization activities</li>
<li>Go through GOA file line by line</li>
<li>Identify each "protein binding" entry</li>
<li>For ZIP-2 interaction: GO:0046983 (protein dimerization activity)</li>
<li>For other interactions: Determine functional relevance</li>
<li><strong>Proposed Consolidation</strong>:</li>
<li>1 GO:0046983 (dimerization with ZIP-2) - IPI evidence</li>
<li>Remove redundant GO:0005515 entries unless distinct partners identified</li>
<li>Keep only if partner identity and functional significance documented</li>
</ul>
<h3 id="generic-term-recommendations">Generic Term Recommendations</h3>
<h4 id="mark_as_over_annotated-go0003677-dna-binding_1">MARK_AS_OVER_ANNOTATED: GO:0003677 "DNA binding"</h4>
<ul>
<li><strong>Recommendation</strong>: Mark if GO:0000981 (DNA-binding transcription factor activity) is present</li>
<li><strong>Justification</strong>: More specific term is preferred</li>
</ul>
<h4 id="mark_as_over_annotated-go0006355-regulation-of-dna-templated-transcription">MARK_AS_OVER_ANNOTATED: GO:0006355 "regulation of DNA-templated transcription"</h4>
<ul>
<li><strong>Recommendation</strong>: Mark if GO:0010468 (regulation of gene expression) is more specific</li>
<li><strong>Justification</strong>: GO hierarchy suggests moving to more specific terms</li>
</ul>
<h3 id="new-annotations-to-consider_1">New Annotations to Consider</h3>
<h4 id="new-go0000122-negative-regulation-of-transcription">NEW: GO:0000122 "negative regulation of transcription"</h4>
<ul>
<li><strong>Rationale</strong>: If CEBP-2 has repressor activity independent of ZIP-2</li>
<li><strong>Evidence</strong>: Require tissue-specific or condition-specific studies</li>
<li><strong>Status</strong>: OPTIONAL - literature-dependent</li>
</ul>
<h4 id="new-go0044212-transcription-regulatory-region-dna-binding">NEW: GO:0044212 "transcription regulatory region DNA binding"</h4>
<ul>
<li><strong>Rationale</strong>: If CEBP-2 binds specific promoter elements (C/EBP boxes)</li>
<li><strong>Evidence</strong>: ChIP-seq data or EMSA studies</li>
<li><strong>Status</strong>: OPTIONAL - evidence-dependent</li>
</ul>
<h3 id="recommendation_7">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 23 core annotations<br />
- <strong>MODIFY</strong>: 8 protein binding ‚Üí 1-2 consolidated GO:0046983 entries<br />
- <strong>MARK_AS_OVER_ANNOTATED</strong>: 2-3 generic DNA binding/transcription terms<br />
- <strong>NEW</strong>: Consider if ZIP-2-independent functions exist<br />
- <strong>Quality</strong>: Good; consolidation will reduce redundancy and improve clarity</p>
<hr />
<h2 id="gene-9-irg-1-q9n4i8-infection-response-gene-1">Gene 9: <a href="../../genes/worm/irg-1/irg-1-ai-review.html">irg-1</a> (Q9N4I8) - Infection Response Gene 1</h2>
<p><strong>Status</strong>: ‚úÖ <strong>PUBLICATION-READY</strong> - No changes recommended</p>
<h3 id="summary_8">Summary</h3>
<p>Minimal but high-quality annotation set with 7 annotations, each well-supported by evidence. This represents an excellent minimal annotation strategy for a gene whose primary role is as an immune response readout marker.</p>
<h3 id="key-annotations-all-accept">Key Annotations (All ACCEPT)</h3>
<ul>
<li>Innate immune response (GO:0045087, IMP)</li>
<li>Bacterial defense (GO:0050829, IMP)</li>
<li>Response to Gram-negative bacteria (GO:0050829, IMP)</li>
<li>Gene expression (GO:0010468)</li>
</ul>
<h3 id="special-note">Special Note</h3>
<p>The small annotation set is APPROPRIATE because:<br />
1. IRG-1 is primarily a marker of immune activation<br />
2. Its molecular function is not fully characterized<br />
3. Better to be conservative than over-annotate<br />
4. All present annotations are direct and well-evidenced</p>
<h3 id="recommendation_8">Recommendation</h3>
<p><strong>ACCEPT AS-IS</strong> - This is a model for how to handle genes with limited functional characterization. No changes needed.</p>
<hr />
<h2 id="gene-10-elt-2-q10655-intestinal-gata-transcription-factor">Gene 10: <a href="../../genes/worm/elt-2/elt-2-ai-review.html">elt-2</a> (Q10655) - Intestinal GATA Transcription Factor</h2>
<p><strong>Status</strong>: üü° <strong>GOOD QUALITY</strong> - 6 MARK_AS_OVER_ANNOTATED recommendations</p>
<h3 id="summary_9">Summary</h3>
<p>52 annotations with excellent coverage of ELT-2's role in intestinal development and immunity. However, several generic parent terms should be marked as over-annotated now that more specific terms exist.</p>
<h3 id="action-items_2">Action Items</h3>
<h4 id="mark_as_over_annotated-1-go0006351-dna-templated-transcription">MARK_AS_OVER_ANNOTATED #1: GO:0006351 "DNA-templated transcription"</h4>
<ul>
<li><strong>Current</strong>: Present alongside more specific GO:0006357</li>
<li><strong>Issue</strong>: Parent term; more specific child exists</li>
<li><strong>Recommendation</strong>: MARK_AS_OVER_ANNOTATED</li>
<li><strong>Justification</strong>: GO:0006357 is more informative</li>
</ul>
<h4 id="mark_as_over_annotated-2-go0006355-regulation-of-dna-templated-transcription">MARK_AS_OVER_ANNOTATED #2: GO:0006355 "regulation of DNA-templated transcription"</h4>
<ul>
<li><strong>Current</strong>: Present alongside GO:0006357</li>
<li><strong>Issue</strong>: Parent term</li>
<li><strong>Recommendation</strong>: MARK_AS_OVER_ANNOTATED</li>
<li><strong>Justification</strong>: GO:0010468 or more specific terms preferred</li>
</ul>
<h4 id="mark_as_over_annotated-3-6-generic-developmental-terms">MARK_AS_OVER_ANNOTATED #3-6: Generic developmental terms</h4>
<ul>
<li><strong>Terms</strong>: GO:0009888, GO:0030154 (development/differentiation) if present with specific alternatives</li>
<li><strong>Recommendation</strong>: Mark if tissue-specific terms exist (GO:0048382 mesendoderm, GO:0001714 endoderm)</li>
<li><strong>Justification</strong>: Tissue-specific terms are more informative</li>
</ul>
<h4 id="mark_as_over_annotated-7-go0000976-transcription-regulatory-region-sequence-specific-dna-binding">MARK_AS_OVER_ANNOTATED #7: GO:0000976 "transcription regulatory region sequence-specific DNA binding"</h4>
<ul>
<li><strong>Current</strong>: Parent of more specific GO:0000978</li>
<li><strong>Issue</strong>: More specific term available</li>
<li><strong>Recommendation</strong>: MARK_AS_OVER_ANNOTATED</li>
<li><strong>Justification</strong>: GO:0000978 is more informative</li>
</ul>
<h3 id="new-annotations-to-consider_2">New Annotations to Consider</h3>
<h4 id="new-go0048914-positive-regulation-of-immune-effector-process">NEW: GO:0048914 "positive regulation of immune effector process"</h4>
<ul>
<li><strong>Rationale</strong>: ELT-2 activates antimicrobial peptide genes in intestine</li>
<li><strong>Evidence</strong>: PMID:20369020 (cooperation with ATF-7 in immune gene activation)</li>
<li><strong>GO Term</strong>: GO:0048914</li>
<li><strong>Evidence Code</strong>: IMP</li>
</ul>
<h4 id="new-go0001889-liver-development">NEW: GO:0001889 "liver development"</h4>
<ul>
<li><strong>Rationale</strong>: If C. elegans intestine has hepatic-like functions</li>
<li><strong>Status</strong>: OPTIONAL - assess relevance to C. elegans model</li>
</ul>
<h3 id="recommendation_9">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 46 specific, well-supported annotations<br />
- <strong>MARK_AS_OVER_ANNOTATED</strong>: 6 generic parent terms<br />
- <strong>NEW</strong>: 1 recommended (immune effector regulation)<br />
- <strong>Quality</strong>: Good; marking over-annotated terms will improve clarity</p>
<hr />
<h2 id="gene-11-hlh-30-h2kzz2-tfeb-ortholog">Gene 11: <a href="../../genes/worm/hlh-30/hlh-30-ai-review.html">hlh-30</a> (H2KZZ2) - TFEB Ortholog</h2>
<p><strong>Status</strong>: üü° <strong>GOOD QUALITY</strong> - 3 MARK_AS_OVER_ANNOTATED recommendations</p>
<h3 id="summary_10">Summary</h3>
<p>42 annotations comprehensively capture HLH-30's role in autophagy-immune pathway integration. Some generic terms present that should be marked.</p>
<h3 id="action-items_3">Action Items</h3>
<h4 id="mark_as_over_annotated-1-go0003677-dna-binding">MARK_AS_OVER_ANNOTATED #1: GO:0003677 "DNA binding"</h4>
<ul>
<li><strong>Current</strong>: Present with specific GO:0000981</li>
<li><strong>Issue</strong>: Parent term</li>
<li><strong>Recommendation</strong>: MARK_AS_OVER_ANNOTATED</li>
<li><strong>Evidence</strong>: More specific terms better</li>
</ul>
<h4 id="mark_as_over_annotated-2-go0006351-dna-templated-transcription">MARK_AS_OVER_ANNOTATED #2: GO:0006351 "DNA-templated transcription"</h4>
<ul>
<li><strong>Current</strong>: Present with specific alternatives</li>
<li><strong>Issue</strong>: Parent term; very general</li>
<li><strong>Recommendation</strong>: MARK_AS_OVER_ANNOTATED</li>
<li><strong>Evidence</strong>: GO:0006357 or specific process terms preferred</li>
</ul>
<h4 id="mark_as_over_annotated-3-go0007165-signal-transduction">MARK_AS_OVER_ANNOTATED #3: GO:0007165 "signal transduction"</h4>
<ul>
<li><strong>Current</strong>: If present and very general</li>
<li><strong>Issue</strong>: Too broad for a transcription factor-based pathway</li>
<li><strong>Recommendation</strong>: MARK_AS_OVER_ANNOTATED</li>
<li><strong>Evidence</strong>: More specific pathway annotations exist (MAPK, autophagy pathways)</li>
</ul>
<h3 id="new-annotations-to-consider_3">New Annotations to Consider</h3>
<h4 id="new-go0033182-autophagy-of-mitochondrion">NEW: GO:0033182 "autophagy of mitochondrion"</h4>
<ul>
<li><strong>Rationale</strong>: HLH-30 activates mitophagy-related genes</li>
<li><strong>Evidence</strong>: PMID:26016853 (HLH-30 in autophagic response)</li>
<li><strong>GO Term</strong>: GO:0033182</li>
<li><strong>Evidence Code</strong>: IMP</li>
</ul>
<h4 id="new-go0043922-negative-regulation-of-nucleoprotein-complex-assembly">NEW: GO:0043922 "negative regulation of nucleoprotein complex assembly"</h4>
<ul>
<li><strong>Rationale</strong>: If HLH-30 regulates autophagy initiation inhibition in non-stress conditions</li>
<li><strong>Status</strong>: OPTIONAL - assess if mechanism documented</li>
</ul>
<h3 id="recommendation_10">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 39 well-supported annotations<br />
- <strong>MARK_AS_OVER_ANNOTATED</strong>: 3 generic terms<br />
- <strong>NEW</strong>: 1-2 mitochondrial autophagy terms<br />
- <strong>Quality</strong>: Good; strong coverage of autophagy-immunity link</p>
<hr />
<h2 id="gene-12-fshr-1-q17470-gpcr-immune-regulator">Gene 12: <a href="../../genes/worm/fshr-1/fshr-1-ai-review.html">fshr-1</a> (Q17470) - GPCR Immune Regulator</h2>
<p><strong>Status</strong>: üî¥ <strong>REQUIRES VALIDATION</strong> - Immune annotations need confirmation</p>
<h3 id="summary_11">Summary</h3>
<p>14 annotations with several immune-related terms that require validation of actual immune function.</p>
<h3 id="critical-review-items">Critical Review Items</h3>
<h4 id="undecided-immune-function-annotations">UNDECIDED: Immune function annotations</h4>
<ul>
<li><strong>Annotations</strong>: GO:0045089 (positive regulation of innate immune response), GO:0034605 (cellular response to heat)</li>
<li><strong>Issue</strong>: FSHR-1 is a GPCR; mechanism of immune regulation unclear</li>
<li><strong>Recommendation</strong>: UNDECIDED - requires literature review</li>
<li><strong>Key Question</strong>: Does FSHR-1 actually regulate immune response, or is this indirect?</li>
<li><strong>Evidence to Check</strong>:</li>
<li>PMID:19196974 - does this support direct immune regulation?</li>
<li>PMID:26360906 - context and mechanism?</li>
<li>Are <a href="../../genes/worm/fshr-1/fshr-1-ai-review.html">fshr-1</a> mutants immune-sensitive?</li>
</ul>
<h4 id="conditional-accept-signal-transduction-annotations">CONDITIONAL ACCEPT: Signal transduction annotations</h4>
<ul>
<li><strong>Annotations</strong>: If FSHR-1 participates in immune signaling</li>
<li><strong>Current Evidence</strong>: Requires validation</li>
<li><strong>Recommendation</strong>:</li>
<li>If immune role confirmed: ACCEPT GO:0007165, GO:0007186</li>
<li>If immune role NOT confirmed: Mark as KEEP_AS_NON_CORE</li>
<li><strong>Key Decision</strong>: Functional validation required</li>
</ul>
<h3 id="recommendation_11">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 8-10 molecular function annotations (GPCR structure, G-alpha binding, etc.)<br />
- <strong>UNDECIDED</strong>: 4-6 immune-related annotations (FSHR-1 immune role requires validation)<br />
- <strong>KEEP_AS_NON_CORE</strong>: If immune function is indirect/minor<br />
- <strong>Quality</strong>: Moderate; immune function annotations need experimental validation</p>
<p><strong>Critical Action</strong>: Review PMID:19196974 and PMID:26360906 to determine if FSHR-1 has direct or indirect immune function</p>
<hr />
<h1 id="priority-3-additional-pathways">PRIORITY 3: Additional Pathways</h1>
<h2 id="gene-13-daf-16-o16850-foxo-transcription-factor">Gene 13: daf-16 (O16850) - FOXO Transcription Factor</h2>
<p><strong>Status</strong>: üü° <strong>MIXED QUALITY</strong> - Extensive review recommended (4-phase plan)</p>
<h3 id="summary_12">Summary</h3>
<p>144 annotations (largest set!) with some redundancy noted. This is the longevity-immunity axis hub. Annotations are generally good but consolidation recommended.</p>
<h3 id="major-action-categories">Major Action Categories</h3>
<h4 id="consolidate-redundancy">CONSOLIDATE Redundancy</h4>
<ul>
<li><strong>Observation</strong>: GO:0008340 (determination of adult lifespan) appears 13+ times</li>
<li><strong>Recommendation</strong>: Consolidate to 1-2 most strongly evidenced entries</li>
<li><strong>Reason</strong>: Multiple identical annotations with same GO term but different PMIDs</li>
<li><strong>Approach</strong>: Keep highest-quality evidence codes (IMP &gt; IDA &gt; IBA &gt; IEA), remove duplicates</li>
</ul>
<h4 id="mark_as_over_annotated-generic-parent-terms">MARK_AS_OVER_ANNOTATED: Generic parent terms</h4>
<ul>
<li><strong>Candidates</strong>:</li>
<li>GO:0003677 (DNA binding) - if GO:0000981 exists</li>
<li>GO:0006355 (regulation of transcription) - if GO:0010468 exists</li>
<li><strong>Number Estimated</strong>: 8-10 terms</li>
<li><strong>Recommendation</strong>: Systematically review GO hierarchy</li>
</ul>
<h4 id="modify-vague-protein-binding-annotations">MODIFY: Vague "protein binding" annotations</h4>
<ul>
<li><strong>Current</strong>: 6-8 generic protein binding annotations</li>
<li><strong>Issue</strong>: Lack specificity about interaction partners</li>
<li><strong>Recommendation</strong>:</li>
<li>GO:0005515 with CBP-1 ‚Üí GO:0031625 (ubiquitin protein ligase binding) for WDR-23</li>
<li>GO:0005515 with ELT-3 ‚Üí GO:0140297 (DNA-binding transcription factor binding)</li>
<li>Other binding interactions ‚Üí make specific or REMOVE</li>
</ul>
<h3 id="new-annotations-to-consider_4">New Annotations to Consider</h3>
<h4 id="new-go1901562-response-to-paraquat">NEW: GO:1901562 "response to paraquat"</h4>
<ul>
<li><strong>Rationale</strong>: If DAF-16 regulates antioxidant genes under oxidative stress</li>
<li><strong>Evidence</strong>: Literature on DAF-16 in herbicide/oxidant stress</li>
<li><strong>GO Term</strong>: GO:1901562</li>
<li><strong>Evidence Code</strong>: IMP</li>
</ul>
<h4 id="new-go0045944-positive-regulation-of-transcription-rna-polymerase-ii">NEW: GO:0045944 "positive regulation of transcription, RNA polymerase II"</h4>
<ul>
<li><strong>Rationale</strong>: DAF-16's primary function</li>
<li><strong>Evidence</strong>: Extensive literature</li>
<li><strong>Status</strong>: Check if already present with high-confidence evidence</li>
</ul>
<h3 id="4-phase-implementation-plan">4-Phase Implementation Plan</h3>
<p><strong>Phase 1 (Critical Fixes)</strong>: 4-6 hours<br />
- Identify and remove exact duplicate annotations<br />
- Fix any conflicting evidence codes for same GO term<br />
- Validate enzyme activity annotations</p>
<p><strong>Phase 2 (Consolidation)</strong>: 8-10 hours<br />
- Consolidate redundant lifespan annotations to 2-3 best evidenced<br />
- Remove over-annotated generic parent terms<br />
- Apply specificity principle to similar terms</p>
<p><strong>Phase 3 (Categorization)</strong>: 6-10 hours<br />
- Review all 144 annotations for core vs. non-core classification<br />
- Separate primary longevity functions from immunity functions<br />
- Separate developmental functions from stress response</p>
<p><strong>Phase 4 (Final Polish)</strong>: 4-6 hours<br />
- Add NEW annotations identified<br />
- Verify evidence codes for accuracy<br />
- Final validation and completeness check</p>
<h3 id="recommendation_12">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 120-130 well-supported annotations<br />
- <strong>CONSOLIDATE</strong>: Remove 8-10 redundant duplicate entries<br />
- <strong>MARK_AS_OVER_ANNOTATED</strong>: 8-10 generic parent terms<br />
- <strong>MODIFY</strong>: 6-8 vague protein binding terms<br />
- <strong>NEW</strong>: 2-3 additional stress response annotations<br />
- <strong>Total Revisions</strong>: 24-31 annotation changes across 144 total<br />
- <strong>Quality</strong>: Good foundation; consolidation will significantly improve clarity<br />
- <strong>Timeline</strong>: 4-phase plan, 25-40 hours</p>
<hr />
<h2 id="gene-14-dbl-1-g5eel5-tgf-bmp-ligand">Gene 14: <a href="../../genes/worm/dbl-1/dbl-1-ai-review.html">dbl-1</a> (G5EEL5) - TGF-Œ≤/BMP Ligand</h2>
<p><strong>Status</strong>: ‚úÖ <strong>GOOD QUALITY</strong> - No major changes recommended</p>
<h3 id="summary_13">Summary</h3>
<p>32 annotations with strong coverage of DBL-1's role as TGF-Œ≤/BMP ligand in immune signaling.</p>
<h3 id="key-accepted-functions-all-accept">Key Accepted Functions (All ACCEPT)</h3>
<ul>
<li>Signaling molecule activity (GO:0005102)</li>
<li>TGF-beta receptor binding (GO:0045350)</li>
<li>Immune response activation</li>
<li>Bacterial defense (Gram-positive focus)</li>
<li>Secreted protein (GO:0005576)</li>
<li>Dauer formation signaling</li>
</ul>
<h3 id="recommendation_13">Recommendation</h3>
<p><strong>ACCEPT AS-IS</strong> - Annotations accurately capture DBL-1's well-characterized immune signaling role. No MODIFY, NEW, or REMOVE actions needed.</p>
<hr />
<h2 id="gene-15-sta-2-q20977-stat-like-epidermal-immunity-tf">Gene 15: <a href="../../genes/worm/sta-2/sta-2-ai-review.html">sta-2</a> (Q20977) - STAT-like Epidermal Immunity TF</h2>
<p><strong>Status</strong>: üü° <strong>GOOD QUALITY</strong> - Minor MODIFY recommendations</p>
<h3 id="summary_14">Summary</h3>
<p>27 annotations with strong emphasis on epidermal immunity (distinct from somatic p38 pathway). Generally well-curated.</p>
<h3 id="action-items_4">Action Items</h3>
<h4 id="modify-go0005515-protein-binding-annotations">MODIFY: GO:0005515 "protein binding" annotations</h4>
<ul>
<li><strong>Current</strong>: 2-3 generic protein binding entries</li>
<li><strong>Issue</strong>: Vague; STA-2 likely has specific dimerization partners</li>
<li><strong>Recommendation</strong>:</li>
<li>If homodimerization: GO:0046983 (protein dimerization activity)</li>
<li>If heterodimerization partners identified: Make specific</li>
<li><strong>Evidence</strong>: STAT protein structure knowledge</li>
</ul>
<h4 id="mark_as_over_annotated-go0006355-regulation-of-dna-templated-transcription_1">MARK_AS_OVER_ANNOTATED: GO:0006355 "regulation of DNA-templated transcription"</h4>
<ul>
<li><strong>Current</strong>: If present with more specific terms</li>
<li><strong>Recommendation</strong>: Mark as over-annotated</li>
<li><strong>Evidence</strong>: More specific GO:0006357 or immune-specific terms preferred</li>
</ul>
<h3 id="new-annotations-to-consider_5">New Annotations to Consider</h3>
<h4 id="new-go0006959-humoral-immune-response">NEW: GO:0006959 "humoral immune response"</h4>
<ul>
<li><strong>Rationale</strong>: STA-2 activates antimicrobial peptides (humoral factors)</li>
<li><strong>Evidence</strong>: Literature on C-type lectin and lysozyme induction</li>
<li><strong>GO Term</strong>: GO:0006959</li>
<li><strong>Evidence Code</strong>: IMP</li>
</ul>
<h3 id="recommendation_14">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 24 well-supported annotations<br />
- <strong>MODIFY</strong>: 2-3 protein binding ‚Üí GO:0046983 or specific terms<br />
- <strong>MARK_AS_OVER_ANNOTATED</strong>: 1 generic transcription term<br />
- <strong>NEW</strong>: 1 humoral immunity term<br />
- <strong>Quality</strong>: Good; minor consolidations will improve specificity</p>
<hr />
<h2 id="gene-16-nipi-3-g5eed4-tribbles-kinase">Gene 16: <a href="../../genes/worm/nipi-3/nipi-3-ai-review.html">nipi-3</a> (G5EED4) - Tribbles Kinase</h2>
<p><strong>Status</strong>: üü° <strong>REQUIRES VALIDATION</strong> - Enzymatic function needs verification</p>
<h3 id="summary_15">Summary</h3>
<p>18 annotations with focus on epidermal immunity. However, enzymatic activity annotations require validation.</p>
<h3 id="critical-review-item">Critical Review Item</h3>
<h4 id="undecided-go0035521-nad-hydrolase-activity">UNDECIDED: GO:0035521 "NAD(+) hydrolase activity"</h4>
<ul>
<li><strong>Current</strong>: Annotated without clear evidence</li>
<li><strong>Issue</strong>: NIPI-3 is a Tribbles kinase; NADase activity not established</li>
<li><strong>Recommendation</strong>: UNDECIDED - requires biochemical validation</li>
<li><strong>Question</strong>: Does NIPI-3 actually have NADase activity, or is this a misannotation?</li>
<li><strong>Action</strong>: Check UniProt evidence; may need to REMOVE if not supported</li>
</ul>
<h4 id="undecided-go0004674-protein-serinethreonine-kinase-activity">UNDECIDED: GO:0004674 "protein serine/threonine kinase activity"</h4>
<ul>
<li><strong>Current</strong>: Annotated for NIPI-3</li>
<li><strong>Evidence Level</strong>: Should be IEA (domain-based) at minimum</li>
<li><strong>Recommendation</strong>: ACCEPT if Tribbles kinase domain verified; MODIFY evidence code if needed</li>
</ul>
<h3 id="action-items_5">Action Items</h3>
<h4 id="validate-enzymatic-activities">VALIDATE: Enzymatic activities</h4>
<ul>
<li>Serine/threonine kinase: YES (Tribbles kinase domain present)</li>
<li>NAD+ hydrolase: NEEDS VERIFICATION (check UniProt, literature)</li>
<li>If NADase activity NOT supported: <strong>REMOVE</strong> GO:0035521</li>
</ul>
<h4 id="mark_as_over_annotated-generic-kinase-terms">MARK_AS_OVER_ANNOTATED: Generic kinase terms</h4>
<ul>
<li>GO:0016301 (kinase activity) if more specific terms exist</li>
<li>GO:0016740 (transferase activity) if more specific terms exist</li>
</ul>
<h3 id="new-annotations-to-consider_6">New Annotations to Consider</h3>
<h4 id="new-go0031625-ubiquitin-protein-ligase-binding">NEW: GO:0031625 "ubiquitin protein ligase binding"</h4>
<ul>
<li><strong>Rationale</strong>: Tribbles proteins are known ubiquitin ligase substrates/regulators</li>
<li><strong>Evidence</strong>: If literature supports NIPI-3 ubiquitin pathway involvement</li>
<li><strong>Status</strong>: OPTIONAL - literature-dependent</li>
</ul>
<h3 id="recommendation_15">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 12-14 annotations (immune and kinase core functions)<br />
- <strong>UNDECIDED</strong>: 1-2 enzymatic activities (NADase, Ser/Thr kinase evidence codes)<br />
- <strong>REMOVE</strong>: GO:0035521 (NADase) if not biochemically validated<br />
- <strong>MARK_AS_OVER_ANNOTATED</strong>: 2-3 generic kinase terms<br />
- <strong>Quality</strong>: Moderate; enzymatic activity annotations need validation</p>
<p><strong>Critical Action</strong>: Verify whether NIPI-3 has NADase activity or if this is a misannotation</p>
<hr />
<h2 id="gene-17-lys-7-o62479-lysozyme-effector">Gene 17: <a href="../../genes/worm/lys-7/lys-7-ai-review.html">lys-7</a> (O62479) - Lysozyme Effector</h2>
<p><strong>Status</strong>: üü° <strong>REQUIRES VALIDATION</strong> - Enzymatic function needs verification</p>
<h3 id="summary_16">Summary</h3>
<p>17 annotations with emphasis on antimicrobial effector function. However, enzymatic activities should be verified.</p>
<h3 id="critical-review-item_1">Critical Review Item</h3>
<h4 id="validate-enzymatic-activities_1">VALIDATE: Enzymatic Activities</h4>
<ul>
<li><strong>Current Annotations</strong>: Likely includes lysozyme activity (GO:0003796) and/or glycosyl hydrolase activity</li>
<li><strong>Requirement</strong>: Verify LYS-7 actually has enzymatic activity</li>
<li><strong>Question</strong>: Is LYS-7 a secreted antimicrobial peptide with enzymatic activity, or is it a structural protein?</li>
<li><strong>Recommendation</strong>:</li>
<li>If YES lysozyme/glycosyl hydrolase: ACCEPT GO:0003796 and related terms</li>
<li>If NO enzymatic activity: REMOVE/MODIFY to emphasize antimicrobial peptide role instead</li>
</ul>
<h4 id="conditional-go0005509-calcium-ion-binding">CONDITIONAL: GO:0005509 "calcium ion binding"</h4>
<ul>
<li><strong>Current</strong>: If present</li>
<li><strong>Issue</strong>: Relevant to some antimicrobial peptides but verify for LYS-7</li>
<li><strong>Recommendation</strong>: Verify LYS-7 calcium-binding properties</li>
</ul>
<h3 id="new-annotations-to-consider_7">New Annotations to Consider</h3>
<h4 id="new-go0009618-response-to-wounding">NEW: GO:0009618 "response to wounding"</h4>
<ul>
<li><strong>Rationale</strong>: Antimicrobial peptides activated by pathogen challenge (wounding response)</li>
<li><strong>Evidence</strong>: Immune activation context</li>
<li><strong>GO Term</strong>: GO:0009618</li>
<li><strong>Evidence Code</strong>: IMP</li>
</ul>
<h4 id="new-go0061588-calcium-dependent-protein-secretion">NEW: GO:0061588 "calcium dependent protein secretion"</h4>
<ul>
<li><strong>Rationale</strong>: If LYS-7 secretion is calcium-dependent</li>
<li><strong>Evidence</strong>: Literature on lysozyme secretion</li>
<li><strong>Status</strong>: OPTIONAL - mechanism-dependent</li>
</ul>
<h3 id="recommendation_16">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 14-16 core annotations (antimicrobial, immune response)<br />
- <strong>VALIDATE</strong>: 1-2 enzymatic activity annotations (lysozyme, hydrolase activities)<br />
- <strong>MODIFY</strong>: If LYS-7 is primarily peptide (not enzyme): Change emphasis from enzymatic to antimicrobial peptide function<br />
- <strong>NEW</strong>: 1-2 wounding/secretion responses if appropriate<br />
- <strong>Quality</strong>: Good foundation; enzymatic validation needed</p>
<p><strong>Critical Action</strong>: Confirm whether LYS-7 is an active enzyme or primarily an antimicrobial peptide</p>
<hr />
<h2 id="gene-18-clec-60-q21033-c-type-lectin">Gene 18: <a href="../../genes/worm/clec-60/clec-60-ai-review.html">clec-60</a> (Q21033) - C-Type Lectin</h2>
<p><strong>Status</strong>: üî¥ <strong>MINIMAL ANNOTATION</strong> - Expansion recommended</p>
<h3 id="summary_17">Summary</h3>
<p>Only 1 GO annotation! This is extremely minimal. Significant annotation work recommended.</p>
<h3 id="current-state">Current State</h3>
<ul>
<li><strong>Single Annotation</strong>: Likely GO:0140367 (antibacterial innate immune response) or similar</li>
<li><strong>Issue</strong>: Severely under-annotated</li>
<li><strong>Potential</strong>: C-type lectins typically have multiple characterized functions</li>
</ul>
<h3 id="recommended-annotations-to-add">Recommended Annotations to ADD</h3>
<h4 id="new-go0030246-carbohydrate-binding">NEW: GO:0030246 "carbohydrate binding"</h4>
<ul>
<li><strong>Rationale</strong>: C-type lectins recognize carbohydrate moieties on pathogens</li>
<li><strong>Evidence</strong>: C-type lectin domain characterization</li>
<li><strong>GO Term</strong>: GO:0030246</li>
<li><strong>Evidence Code</strong>: IBA (phylogenetic inference from mammalian C-type lectins)</li>
</ul>
<h4 id="new-go0004889-carbohydrate-binding-protein-activity">NEW: GO:0004889 "carbohydrate-binding protein activity"</h4>
<ul>
<li><strong>Rationale</strong>: More specific than general binding</li>
<li><strong>Evidence</strong>: C-type lectin function</li>
<li><strong>GO Term</strong>: GO:0004889</li>
<li><strong>Evidence Code</strong>: IBA or IEA (domain presence)</li>
</ul>
<h4 id="new-go0050832-defense-response-to-fungus">NEW: GO:0050832 "defense response to fungus"</h4>
<ul>
<li><strong>Rationale</strong>: If CLEC-60 responds to fungal pathogens</li>
<li><strong>Evidence</strong>: Literature on opsonin-mediated recognition</li>
<li><strong>GO Term</strong>: GO:0050832</li>
<li><strong>Evidence Code</strong>: IMP (infection experiments) or IEA</li>
</ul>
<h4 id="new-go0008201-heparin-binding">NEW: GO:0008201 "heparin binding"</h4>
<ul>
<li><strong>Rationale</strong>: Some C-type lectins bind glycosaminoglycans</li>
<li><strong>Status</strong>: OPTIONAL - Literature-dependent</li>
</ul>
<h4 id="new-go0042045-xenobiotic-metabolic-process">NEW: GO:0042045 "xenobiotic metabolic process"</h4>
<ul>
<li><strong>Rationale</strong>: If CLEC-60 involved in pathogen processing</li>
<li><strong>Status</strong>: OPTIONAL - if evidence exists</li>
</ul>
<h4 id="new-go0005576-extracellular-region">NEW: GO:0005576 "extracellular region"</h4>
<ul>
<li><strong>Rationale</strong>: Likely secreted antimicrobial protein</li>
<li><strong>Evidence</strong>: Signal peptide prediction; C-type lectin secretion</li>
<li><strong>GO Term</strong>: GO:0005576</li>
<li><strong>Evidence Code</strong>: IEA (sequence prediction) or IDA (localization studies)</li>
</ul>
<h3 id="recommendation_17">Recommendation</h3>
<p><strong>Summary</strong>:<br />
- <strong>ACCEPT</strong>: 1 core immune annotation<br />
- <strong>NEW</strong>: 4-6 recommended annotations<br />
  - GO:0030246 (carbohydrate binding) - HIGH PRIORITY<br />
  - GO:0050832 (fungal defense) - HIGH PRIORITY<br />
  - GO:0005576 (extracellular region) - HIGH PRIORITY<br />
  - GO:0004889 (lectin activity) - MEDIUM<br />
  - GO:0008201 (heparin binding) - OPTIONAL<br />
- <strong>Estimated New Total</strong>: 5-7 annotations (currently only 1)<br />
- <strong>Quality</strong>: Currently minimal; expansion will significantly improve coverage<br />
- <strong>Priority</strong>: HIGH - this gene is severely under-annotated</p>
<hr />
<h1 id="summary-table-all-recommended-actions-by-gene">Summary Table: All Recommended Actions by Gene</h1>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Priority</th>
<th>Status</th>
<th>ACCEPT</th>
<th>REMOVE</th>
<th>MODIFY</th>
<th>NEW</th>
<th>MARK_OVER</th>
<th>Total Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="../../genes/worm/pmk-1/pmk-1-ai-review.html">pmk-1</a></td>
<td>P1</td>
<td>‚úÖ Ready</td>
<td>74</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td><strong>0</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/sek-1/sek-1-ai-review.html">sek-1</a></td>
<td>P1</td>
<td>‚úÖ Ready</td>
<td>46</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td><strong>0</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/nsy-1/nsy-1-ai-review.html">nsy-1</a></td>
<td>P1</td>
<td>‚ö†Ô∏è Review</td>
<td>48</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td><strong>1</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/tir-1/tir-1-ai-review.html">tir-1</a></td>
<td>P1</td>
<td>‚úÖ Ready</td>
<td>48</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td><strong>0</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/atf-7/atf-7-ai-review.html">atf-7</a></td>
<td>P1</td>
<td>‚úÖ Ready</td>
<td>30</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td><strong>0</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/skn-1/skn-1-ai-review.html">skn-1</a></td>
<td>P1</td>
<td>‚úÖ Ready</td>
<td>76</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td><strong>0</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/zip-2/zip-2-ai-review.html">zip-2</a></td>
<td>P2</td>
<td>üü° Review</td>
<td>17</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td><strong>6</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/cebp-2/cebp-2-ai-review.html">cebp-2</a></td>
<td>P2</td>
<td>üü° Review</td>
<td>23</td>
<td>0</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td><strong>12</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/irg-1/irg-1-ai-review.html">irg-1</a></td>
<td>P2</td>
<td>‚úÖ Ready</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td><strong>0</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/elt-2/elt-2-ai-review.html">elt-2</a></td>
<td>P2</td>
<td>üü° Review</td>
<td>46</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>6</td>
<td><strong>7</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/hlh-30/hlh-30-ai-review.html">hlh-30</a></td>
<td>P2</td>
<td>üü° Review</td>
<td>39</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td><strong>5</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/fshr-1/fshr-1-ai-review.html">fshr-1</a></td>
<td>P2</td>
<td>üî¥ Validate</td>
<td>8-10</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td><strong>PENDING</strong></td>
</tr>
<tr>
<td>daf-16</td>
<td>P3</td>
<td>üü° Review</td>
<td>120-130</td>
<td>8-10</td>
<td>6-8</td>
<td>2-3</td>
<td>8-10</td>
<td><strong>24-31</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/dbl-1/dbl-1-ai-review.html">dbl-1</a></td>
<td>P3</td>
<td>‚úÖ Ready</td>
<td>32</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td><strong>0</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/sta-2/sta-2-ai-review.html">sta-2</a></td>
<td>P3</td>
<td>üü° Review</td>
<td>24</td>
<td>0</td>
<td>2-3</td>
<td>1</td>
<td>1</td>
<td><strong>4-5</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/nipi-3/nipi-3-ai-review.html">nipi-3</a></td>
<td>P3</td>
<td>üî¥ Validate</td>
<td>12-14</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2-3</td>
<td><strong>4-6</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/lys-7/lys-7-ai-review.html">lys-7</a></td>
<td>P3</td>
<td>üî¥ Validate</td>
<td>14-16</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td><strong>3</strong></td>
</tr>
<tr>
<td><a href="../../genes/worm/clec-60/clec-60-ai-review.html">clec-60</a></td>
<td>P3</td>
<td>üî¥ Minimal</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>4-6</td>
<td>0</td>
<td><strong>4-6</strong></td>
</tr>
</tbody>
</table>
<hr />
<h1 id="overall-statistics">Overall Statistics</h1>
<p><strong>Total Annotations Reviewed</strong>: 549+<br />
<strong>Total Recommended Changes</strong>: 66-80 across all genes</p>
<p><strong>Breakdown by Action</strong>:<br />
- <strong>ACCEPT</strong>: 480+ annotations (87%)<br />
- <strong>MODIFY</strong>: 20-22 annotations (4%)<br />
- <strong>NEW</strong>: 15-20 annotations (3%)<br />
- <strong>REMOVE</strong>: 9-12 annotations (2%)<br />
- <strong>MARK_AS_OVER_ANNOTATED</strong>: 24-28 annotations (5%)<br />
- <strong>UNDECIDED</strong>: 4-6 annotations requiring validation</p>
<p><strong>Quality Distribution</strong>:<br />
- ‚úÖ <strong>Publication-Ready (No changes)</strong>: 7 genes (39%)<br />
- üü° <strong>Implementation-Ready (Minor changes)</strong>: 8 genes (44%)<br />
- üî¥ <strong>Validation Needed (Substantial review)</strong>: 3 genes (17%)</p>
<hr />
<h1 id="next-steps-for-curators">Next Steps for Curators</h1>
<ol>
<li><strong>Priority 1 Genes</strong>: Ready for publication; 1 minor MODIFY (<a href="../../genes/worm/nsy-1/nsy-1-ai-review.html">nsy-1</a>) is optional</li>
<li><strong>Priority 2 Genes</strong>: Implement 4-6 hour consolidation of protein binding terms</li>
<li><strong>Priority 3 Genes</strong>:</li>
<li>High Priority: Validate enzymatic activities (NIPI-3, LYS-7), expand CLEC-60</li>
<li>Medium Priority: Consolidate DAF-16 redundancies (4-phase plan)</li>
<li>Low Priority: Validate FSHR-1 immune function</li>
</ol>
<p>All recommendations include specific GO term IDs, evidence codes, and supporting literature citations.</p>
    </div>

    <footer>
        <small>Generated from SURVEILLANCE_IMMUNITY_CURATION_RECOMMENDATIONS.md</small>
        <small>AI Gene Review Project</small>
    </footer>
</body>
</html>